ReviewPrzeglad menopauzalny = Menopause review2025
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.
Review in Przeglad menopauzalny = Menopause review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The outcomes of laparoscopic surgeries for urinary bladder and vesicouterine pouch endometriosis in the Polish population.Przeglad menopauzalny = Menopause review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of life (QoL), including anaemia, pain, and pressure-related symptoms. Additionally, fibroids are the sole cause of infertility in 1-3% of women. Endometriosis is the most common gynaecological cause of chronic pelvic pain syndrome and one of the leading causes of infertility. This condition affects between 2% and 10% of women, leading to symptoms that often have a detrimental impact on QoL. For decades, efforts have been underway to develop pharmacological treatments for oestrogen-dependent conditions that would offer both high efficacy and good tolerability. A significant advancement in the treatment of oestrogen-dependent diseases was the introduction into clinical practice of gonadotropin-releasing hormone (GnRH) antagonists. In recent years, publications have demonstrated the promising therapeutic potential of linzagolix in the management of uterine fibroids and endometriosis. It is an oral, small-molecule, non-peptide GnRH antagonist that induces dose-dependent suppression of ovarian function. The aim of this literature review was to evaluate current evidence on the potential applications of linzagolix for the treatment of uterine fibroids and endometriosis. Linzagolix, with or without add-back therapy, significantly alleviates the symptoms of both uterine fibroids and endometriosis in a dose-dependent manner - the therapeutic effect is rapid and sustained. This drug constitutes a valuable addition to existing methods for treating oestrogen-dependent diseases because it enables treatment personalisation allowing for dose adjustment and the optional use of add-back therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.